STATEMENT OF NEED
Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and comprises almost 30 percent of all newly diagnosed tumors in humans. Although a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and thus the topic of extensive ongoing clinical research. To this end, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for oncologists, urologists and other cancer clinicians who provide care for these patients. These proceedings from an interactive case-based meeting held during the 2011 Genitourinary Cancers Symposium will offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.
TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.
LEARNING OBJECTIVES
- Use evidence-based molecular and clinical factors to refine prognosis and treatment recommendations for patients with prostate cancer (PC).
- Apply case-based learning to the best-practice delivery of systemic therapy for patients with locally advanced and metastatic PC.
- Educate patients with castration-resistant PC (CRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
- Counsel patients about the efficacy and safety of immunotherapy for patients with asymptomatic and symptomatic CRPC.
- Explore the emerging data and active research evaluating novel agents in the setting of advanced PC, and discuss the biologic basis for their clinical activity.
- Communicate the availability of ongoing clinical trial participation to appropriately selected patients with PC.
ACCREDITATION STATEMENT
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The Duke University School of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the MP3s and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/GUCancers/CME.
This CME activity is supported by educational grants from Dendreon Corporation and sanofi aventis U.S.
UNAPPROVED USE DISCLOSURE
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will not be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
CO-CHAIRS
Daniel J George, MD
Associate Professor of Medicine and Surgery
Director of Genitourinary Oncology
Duke Medical Center
Durham, North Carolina
Neil Love, MD
President
Research To Practice
Miami, Florida
FACULTY AFFLIATIONS
Stephen J Freedland, MD
Attending Physician, Durham VA Medical Center
Associate Professor of Urology and Pathology
Duke Prostate Center
Duke University School of Medicine
Durham, North Carolina
Philip Kantoff, MD
Chief Clinical Research Officer
Chief, Division of Solid Tumor Oncology
Director of the Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
William K Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan MD Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York
A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Piltz Endowed Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana
TREATING ONCOLOGISTS
Andrew J Armstrong, MD, ScM
Assistant Professor of Medicine and Surgery
Duke Cancer Institute and the
Duke Prostate Center
Departments of Medicine and Surgery
Divisions of Medical Oncology and Urology
Durham, North Carolina
Philip T Glynn, MD
Director of Oncology
Noble Hospital
Assistant Clinical Professor
Tufts University School of Medicine
Springfield, Massachusetts
Manjesh Lingamurthy, MD
Hematology/Oncology
Michael and Dianne Bienes
Comprehensive Cancer Center
Holy Cross Hospital
Fort Lauderdale, Florida
Erik J Rupard, MD, LTC
Chief, Hematology-Oncology Service
Dwight David Eisenhower Army Medical Center
Assistant Professor at Medical College of Georgia
Assistant Professor at Uniformed Services University of the Health Sciences
Ft Gordon, Georgia
RESOLUTION OF CONFLICTS OF INTEREST
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
FACULTY DISCLOSURES — The following speakers and/or planning committee members have indicated they have no relationship(s) with industry to disclose relative to the content of the CME activity: Drs Glynn, Lingamurthy, Love and Rupard. The following speakers and/or planning committee members have indicated that they have relationship(s) with industry to disclose: Dr Armstrong — Advisory Board Member: Active Biotech, Bristol-Myers Squibb; Consultant: Active Biotech, Amgen, Dendreon; Principal Investigator: Active Biotech, Bristol-Myers Squibb, Dendreon, Eli Lilly, Imclone, Medivation, Novartis, Pfizer, sanofi aventis; Speaker: Dendreon, Pfizer, sanofi aventis. Dr Freedland — Advisory Board Member: Amgen, Astra Zeneca, Bayer Pharmaceuticals, Dendreon, GlaxoSmithKline, Johnson & Johnson; Speaker: Amgen, Astra Zeneca, Johnson & Johnson. Dr George — Advisory Board Member: sanofi aventis; Consultant: Dendreon, Genentech, Novartis, Pfizer; Principal Investigator: Bristol-Myers Squibb, Dendreon, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer; Speaker: Dendreon, Genentech, Novartis, Pfizer, sanofi aventis. Dr Kantoff — Advisory Board Member: BIND; Consultant: Amgen, Bellicum, BI Immunotherapeutics, Genentech, Johnson & Johnson, Ortho Biotech, Pfizer, Tokai. Dr Oh — Advisory Board Member: Bellicum, sanofi aventis; Consultant: Amgen, Genentech, Johnson & Johnson, Pfizer; Principal Investigator: Millennium. Dr Sartor — Consultant: Amgen, Astra Zeneca, Johnson & Johnson; Principal Investigator: Astra Zeneca, GlaxoSmithKline, Johnson & Johnson, sanofi aventis.
STAFF AND CONTENT VALIDATION REVIEWER DISCLOSURES — The staff involved in the planning and content development of this activity have reported no relevant financial relationships with commercial interests.
DISCLAIMER
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: June 20, 2011
Expiration date: June 19, 2012
